AMAG Pharmaceuticals (AMAG Pharmaceuticals) Accounts Payable & Accrued Expense : $156.3 Mil (As of Sep. 2020)

View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals Accounts Payable & Accrued Expense?

AMAG Pharmaceuticals's quarterly accounts payable & accrued expense declined from Mar. 2020 ($184.2 Mil) to Jun. 2020 ($157.5 Mil) and declined from Jun. 2020 ($157.5 Mil) to Sep. 2020 ($156.3 Mil).

AMAG Pharmaceuticals's annual accounts payable & accrued expense declined from Dec. 2017 ($174.4 Mil) to Dec. 2018 ($149.1 Mil) but then increased from Dec. 2018 ($149.1 Mil) to Dec. 2019 ($210.4 Mil).

AMAG Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for AMAG Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals Accounts Payable & Accrued Expense Chart

AMAG Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

111.27

159.69

174.45

149.12

210.40

AMAG Pharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															198.84	210.40	184.18	157.51	156.34

AMAG Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.amagpharma.com

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.

Executives

Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano	officer: Chief Operating Officer	C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos	officer: Interim CFO	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson	director, 10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat	director
Davey Scoon	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers	director, officer: President & CEO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick	officer: Chief Human Resources Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022